Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.

This network meta-analysis found that atezolizumab plus bevacizumab provides the best balance between QoL preservation and overall survival benefit compared to other systemic therapy options in unresectable or advanced HCC. This integrated assessment of survival and quality of life outcomes offers a more patient-centered approach for treatment selection in clinical practice.